Botanix Pharmaceuticals (ASX:BOT) said that the commercial launch of its lead dermatology product, Sofdra, a topical gel for treating excessive underarm sweating, remains "on track," according to a Monday filing with the Australian bourse.
The company's sales team is performing in line with expectations, and the full digital launch expected this month will further drive prescription volume, per the filing.
Growth in new patient prescriptions is also on track, with refill rates exceeding targets, the filing added.
The company also said it does not expect any material impact from tariffs on Sofdra.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。